PARSIPPANY, N.J.--(

新泽西州帕西帕尼--(

BUSINESS WIRE

商业热线

)--Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is labelled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonable expectation of efficacy based on serology data..

)--Zoetis今天宣布，美国农业部（USDA）兽医生物制品中心（CVB）已向该公司发放H5N2亚型禽流感灭活病毒疫苗的有条件许可证。这种疫苗贴上了用于鸡的标签。有条件的许可证是基于血清学数据证明安全性，纯度和合理的疗效预期而授予的。。

Zoetis is committed to supporting poultry producers with scientific solutions for Highly Pathogenic Avian Influenza (HPAI). The decision to vaccinate commercial poultry flocks against HPAI rests solely with national regulatory authorities in partnership with the poultry industry.

Zoetis致力于为家禽生产者提供高致病性禽流感（HPAI）的科学解决方案。为商业家禽群接种高致病性禽流感疫苗的决定完全取决于国家监管机构与家禽业的合作。

According to the USDA’s Animal and Plant Health Inspection Service (

根据美国农业部动植物卫生检查局(

APHIS

蚜虫

), more than 150 million birds in the U.S. have been affected with HPAI since February 2022, including in backyard and commercial flocks. A conditional license is used to meet an emergency condition, limited market, local situation or other special circumstance and is issued for a finite period of time.

)自2022年2月以来，美国已有1.5亿多只鸟类受到高致病性禽流感的影响，包括后院和商业鸟类。有条件的许可证用于满足紧急情况、有限的市场、当地情况或其他特殊情况，并在有限的时间内发放。

Conditional licenses may be renewed at the discretion of the CVB..

有条件的许可证可由CVB自行决定续期。。

“

“

When a new strain of HPAI was identified in the U.S. in early 2022, our scientists immediately began work to update our previous avian influenza vaccine,” said Mahesh Kumar, Ph.D., senior vice president, global biologics research and development at Zoetis. “

当2022年初在美国发现一种新的高致病性禽流感病毒株时，我们的科学家立即开始更新我们以前的禽流感疫苗，”佐蒂斯全球生物制剂研究与开发高级副总裁Mahesh Kumar博士说。“”

We first worked on HPAI vaccines in 2001-02 when outbreaks occurred in flocks in Southeast Asia. Our readiness with this most recent vaccine is another example of how we continue to live our purpose to nurture the world and humankind by advancing care for animals, ultimately providing solutions to global animal health challenges.”.

我们于2001-02年首次研究高致病性禽流感疫苗，当时东南亚发生了禽流感疫情。。

Zoetis has a long history of developing vaccines to address avian influenza in multiple countries. In 2016, the company received a conditional license for its H5N1 vaccine and a contract award for the USDA’s National Veterinary Stockpile; this same vaccine was first used by the U.S. Fish & Wildlife Service in 2023 to help protect California condors.

Zoetis在多个国家开发疫苗以应对禽流感方面有着悠久的历史。；2023年，美国鱼类和野生动物管理局首次使用这种疫苗来帮助保护加利福尼亚秃鹰。

Zoetis also holds a USDA license for POULVAC.

Zoetis还持有POULVAC的美国农业部许可证。

®

®

FLUFEND™ i AI H5N3 RG which has been available in smaller markets outside the U.S. and was used to help protect endangered birds in New Zealand in 2024.

FLUFEND™i AI H5N3 RG已在美国以外的较小市场上市，并于2024年用于帮助保护新西兰的濒危鸟类。

About Zoetis

关于Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers.

作为世界领先的动物保健公司，Zoetis有一个独特的目标：通过促进对动物的护理来培育我们的世界和人类。在70多年来不断创新预测、预防、检测和治疗动物疾病的方法之后，Zoetis继续支持世界各地饲养和照顾动物的人，从兽医、宠物主人到牲畜生产者。

The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit .

该公司领先的药物、疫苗、诊断和技术组合和管道在100多个国家发挥了重要作用。作为财富500强企业，Zoetis在2024年创造了93亿美元的收入，拥有约13800名员工。有关更多信息，请访问。

www.zoetis.com

www.zoetis.com

.

.

DISCLOSURE NOTICES

披露通知

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to expectations regarding products, product approvals or licenses, products under development and other future events. These statements are not guarantees of future performance or actions.

前瞻性声明：本新闻稿包含前瞻性声明，反映了Zoetis对产品、产品批准或许可、正在开发的产品和其他未来事件的期望的当前观点。这些声明并不能保证未来的表现或行动。

Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made.

前瞻性陈述具有风险和不确定性。如果这些风险或不确定性中的一个或多个成为现实，或者如果管理层的基本假设被证明是不正确的，则实际结果可能与前瞻性声明所预期的结果存在重大差异。前瞻性声明仅在作出之日起生效。

Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “.

Zoetis明确否认任何更新或修改任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。有关风险、不确定性和其他事项的进一步列表和描述，请参见我们最近的年度报告中的表格10-K，包括标题部分”。

Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at

表10-Q中的季度报告和表8-K中的当前报告中的“可能影响未来结果的前瞻性陈述和因素”和“第1A项风险因素”。这些文件和后续文件可在网上查阅

www.sec.gov

www.sec.gov

,

,

www.zoetis.com

www.zoetis.com

, or on request from Zoetis.

，或应Zoetis的要求。

ZTS-COR

ZTS-COR

ZTS-IR

ZTS-IR

ZTS-FA

ZTS-FA